Results 11 to 20 of about 272,512 (195)

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification [PDF]

Proceedings of the National Academy of Sciences, 2012
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor prognosis. However, tumors without MYCN
Valentijn, Linda J., Koster, Jan, Haneveld, Franciska, Aissa, Rachida Ait, van Sluis, Peter, Broekmans, Marloes E. C., Molenaar, Jan J., van Nes, Johan, Versteeg, Rogier   +8 more
openaire   +4 more sources

Radiogenomics prediction for MYCN amplification in Neuroblastoma: a hypothesis generating study [PDF]

Pediatric Blood & Cancer, 2021
Background: MYCN amplification represents a powerful prognostic factor in neuroblastoma (NB) and may occasionally account for intratumoral heterogeneity. Radiomics is an emerging field of advanced image analysis that aims to extract a large number of quantitative features from standard radiological images, providing valuable clinical information ...
Angela Di Giannatale, Pier Luigi Di Paolo, Davide Curione, Jacopo Lenkowicz, Antonio Napolitano, Aurelio Secinaro, Paolo Tomà, Franco Locatelli, Aurora Castellano, Luca Boldrini   +9 more
openaire   +4 more sources

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma

Cancer Cell International, 2017
Background MYCN gene amplification is related to risk stratification. Therefore it is important to identify accurately the level of the MYCN gene as early as possible in neuroblastoma (NB); however, for patients with bone marrow (BM) metastasis who need ...
Zhi-Xia Yue, Cheng Huang, Chao Gao, Tian-Yu Xing, Shu-Guang Liu, Xing-Jun Li, Qian Zhao, Xi-Si Wang, Wen Zhao, Mei Jin, Xiao-Li Ma   +10 more
doaj   +2 more sources

MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines

Molecular Medicine Reports, 2018
Neuroblastoma derived from primitive sympathetic neural precursors is a common type of solid tumor in infants. MYCN proto‑oncogene bHLH transcription factor (MYCN) amplification and 1p36 deletion are important factors associated with the poor prognosis of neuroblastoma.
Altungöz, Oğuz, Aygun, Nevim
openaire   +5 more sources

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma [PDF]

Nature Genetics, 2018
Amplification of the locus encoding the oncogenic transcription factor MYCN is a defining feature of high-risk neuroblastoma. Here we present the first dynamic chromatin and transcriptional landscape of MYCN perturbation in neuroblastoma. At oncogenic levels, MYCN associates with E-box binding motifs in an affinity-dependent manner, binding to strong ...
Rhamy Zeid, Matthew A. Lawlor, Evon Poon, Jaime M. Reyes, Mariateresa Fulciniti, Michael A. Lopez, Thomas G. Scott, Behnam Nabet, Michael A. Erb, Georg E. Winter, Zoe Jacobson, Donald R. Polaski, Kristen L. Karlin, Rachel A. Hirsch, Nikhil P. Munshi, Thomas F. Westbrook, Louis Chesler, Charles Y. Lin, James E. Bradner   +18 more
openaire   +5 more sources

High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma [PDF]

Acta Neuropathologica Communications, 2020
We report a novel group of clinically aggressive spinal cord ependymomas characterized by Grade III histology, MYCN amplification, an absence of NF2 alterations or other recurrent pathogenic mutations, and a unique methylation classifier profile.
Mark Raffeld, Zied Abdullaev, Svetlana D. Pack, Liqiang Xi, Sushma Nagaraj, Nicole Briceno, Elizabeth Vera, Stefania Pittaluga, Osorio Lopes Abath Neto, Martha Quezado, Kenneth Aldape, Terri S. Armstrong, Mark R. Gilbert   +12 more
doaj   +2 more sources

Regulation of MYCN expression in human neuroblastoma cells [PDF]

BMC Cancer, 2009
Background Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB.
de Vries I, Hulsbergen-van de Kaa Christina A, van Leeuwen Frank N, van Bokhoven Hans, Jacobs Joannes FM, Adema Gosse J, Hoogerbrugge Peter M, de Brouwer Arjan PM   +7 more
doaj   +4 more sources

Radiomics-Based Machine Learning for Determining Amplification Status in Childhood Neuroblastoma: A Systematic Review and Meta-Analysis [PDF]

Technology in Cancer Research & Treatment
Introduction The MYCN oncogene promotes tumor cell proliferation in neuroblastoma, and its amplification is a well-established marker of poor prognosis. Radiomics-based approaches have shown promise in noninvasively determining MYCN amplification status;
Haoru Wang MD, Yi Ji MD, Xin Chen MD, Ling He MD, Xiangming Fang MD, Jinhua Cai MD   +5 more
doaj   +2 more sources

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. [PDF]

Br J Cancer, 2018
In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA).
Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.   +23 more
europepmc   +7 more sources

MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma [PDF]

International Journal of Molecular Sciences, 2023
Mohammad Alzrigat, Lars-Gunnar Larsson, Prasoon Agarwal   +2 more
exaly   +2 more sources